Information:
Fel:
ID
39687
Beskrivning
Safety and Efficacy of Vaniprevir (MK-7009) With Pegylated Interferon (Peg-IFN) and Ribavirin (RBV) in Treatment-Experienced Hepatitis C Virus (HCV) Participants (MK-7009-009); ODM derived from: https://clinicaltrials.gov/show/NCT00704405
Länk
https://clinicaltrials.gov/show/NCT00704405
Nyckelord
Versioner (1)
- 2020-02-10 2020-02-10 -
Rättsinnehavare
See clinicaltrials.gov
Uppladdad den
10 februari 2020
DOI
För en begäran logga in.
Licens
Creative Commons BY 4.0
Modellkommentarer :
Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.
Itemgroup-kommentar för :
Item-kommentar för :
Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.
Eligibility Hepatitis C, Chronic NCT00704405
Eligibility Hepatitis C, Chronic NCT00704405
- StudyEvent: Eligibility
Similar models
Eligibility Hepatitis C, Chronic NCT00704405
- StudyEvent: Eligibility
Name
Typ
Description | Question | Decode (Coded Value)
Datatyp
Alias
Chronic Hepatitis C Genotype
Item
has chronic hcv genotype 1 infection
boolean
C0524910 (UMLS CUI [1,1])
C1533728 (UMLS CUI [1,2])
C1533728 (UMLS CUI [1,2])
Therapy Experience
Item
is treatment-experienced
boolean
C0087111 (UMLS CUI [1,1])
C0596545 (UMLS CUI [1,2])
C0596545 (UMLS CUI [1,2])
Liver Cirrhosis Absent Biopsy of liver | Liver carcinoma Absent Biopsy of liver | Liver Cirrhosis Biopsy of liver
Item
for the non-cirrhotic population, has had a liver biopsy without evidence of cirrhosis and hepatocellular carcinoma; for the cirrhotic population, has had a liver biopsy with evidence of cirrhosis and without evidence of hepatocellular carcinoma.
boolean
C0023890 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0193388 (UMLS CUI [1,3])
C2239176 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0193388 (UMLS CUI [2,3])
C0023890 (UMLS CUI [3,1])
C0193388 (UMLS CUI [3,2])
C0332197 (UMLS CUI [1,2])
C0193388 (UMLS CUI [1,3])
C2239176 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0193388 (UMLS CUI [2,3])
C0023890 (UMLS CUI [3,1])
C0193388 (UMLS CUI [3,2])
Intolerance to PEGINTERFERON/RIBAVIRIN Previous
Item
has not tolerated previous course peg-ifn and rbv
boolean
C1744706 (UMLS CUI [1,1])
C1875630 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
C1875630 (UMLS CUI [1,2])
C0205156 (UMLS CUI [1,3])
Intolerance to PEGINTERFERON/RIBAVIRIN Duration
Item
is unlikely to tolerate at least 24 weeks of continuous therapy with peg-ifn and rbv
boolean
C1744706 (UMLS CUI [1,1])
C1875630 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
C1875630 (UMLS CUI [1,2])
C0449238 (UMLS CUI [1,3])
Human immunodeficiency virus (HIV) coinfection | HBV coinfection
Item
is co-infected with human immunodeficiency virus (hiv) and/or hepatitis b
boolean
C4062778 (UMLS CUI [1])
C2242656 (UMLS CUI [2])
C2242656 (UMLS CUI [2])
Alcohol intake above recommended sensible limits
Item
consumes excessive amounts of alcohol
boolean
C0560219 (UMLS CUI [1])
Substance Use Disorders
Item
has a history of drug or alcohol abuse
boolean
C0038586 (UMLS CUI [1])
Pregnancy | Breast Feeding
Item
if female, participant is pregnant or breastfeeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
C0006147 (UMLS CUI [2])
Study Subject Participation Status | Investigational New Drugs
Item
has been in a clinical trail with an investigational drug in the last 30 days
boolean
C2348568 (UMLS CUI [1])
C0013230 (UMLS CUI [2])
C0013230 (UMLS CUI [2])
Use of Interferon Recent | Use of PEGINTERFERON Recent | Use of Ribavirin Recent
Item
has used ifn/peg-ifn and rbv in the last 3 months
boolean
C1524063 (UMLS CUI [1,1])
C3652465 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C1524063 (UMLS CUI [2,1])
C0982327 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C1524063 (UMLS CUI [3,1])
C0035525 (UMLS CUI [3,2])
C0332185 (UMLS CUI [3,3])
C3652465 (UMLS CUI [1,2])
C0332185 (UMLS CUI [1,3])
C1524063 (UMLS CUI [2,1])
C0982327 (UMLS CUI [2,2])
C0332185 (UMLS CUI [2,3])
C1524063 (UMLS CUI [3,1])
C0035525 (UMLS CUI [3,2])
C0332185 (UMLS CUI [3,3])